Cell News and Research

RSS

MRS imaging technique may help diagnose chronic traumatic encephalopathy

In a study of ex-pro athletes, researchers found that a specialized imaging technique called magnetic resonance spectroscopy (MRS) may help diagnose chronic traumatic encephalopathy (CTE), a disorder caused by repetitive head trauma that currently can only be definitively diagnosed at autopsy. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

1 Dec 2010

Mitochondrial dysfunction observed in children with full syndrome autism

Preliminary research has found that children with autism are more likely to have impaired mitochondrial function (structures within cells responsible for energy production) and mitochondrial DNA abnormalities than typically developing children, according to a study in the December 1 issue of JAMA.

1 Dec 2010

PhRMA reports 100 new medicines and vaccines in development for HIV/AIDS

America's biopharmaceutical research companies are working on 100 new medicines and vaccines [video] to treat and prevent HIV/AIDS and related conditions, according to a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA).

1 Dec 2010

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.

1 Dec 2010

Research on patients' immune system may lead to new diagnostic tool for HIV treatment

Mayo Clinic researchers have shown why, in a minority of HIV patients, immune function improves despite a lack of response to standard anti-retroviral treatment. In these cases, researchers say, the virus has lost its ability to kill immune cells. The findings appear in the online journal PLoS Pathogens.

1 Dec 2010

Scientists create couch potato mouse model to study muscle function

Daniel Kelly, M.D., and his colleagues at Sanford-Burnham Medical Research Institute (Sanford-Burnham) at Lake Nona have unveiled a surprising new model for studying muscle function: the couch potato mouse.

1 Dec 2010

Living Donor Paired Exchange becomes first Canada-wide organ donation registry

Yesterday, the Living Donor Paired Exchange performed the first match run to include kidney patients and donors from all across Canada. In doing so, it became the first Canada-wide organ donation registry.

1 Dec 2010

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

The National Comprehensive Cancer Network has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clinical activity of axitinib in various tumor types.

1 Dec 2010

Elorac's naloxone lotion receives FDA Orphan Drug Designation for pruritus associated with mycosis fungoides

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders announced that it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for its naloxone lotion for the topical treatment of pruritus accompanying cutaneous t-cell lymphoma (CTCL, also known as mycosis fungoides).

1 Dec 2010

ACT files IND application to initiate Phase I/II study for Dry AMD

Advanced Cell Technology, Inc. announced today that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).

30 Nov 2010

NIA awards Aphios Phase I Fast Track SBIR grant for development of novel AD nanodrug

Aphios® Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute of Aging (NIA), National Institutes of Health (NIH) for Developing a Novel Alzheimer's Disease Nanodrug.

30 Nov 2010

NSAID Celebrex may help prevent non-melanoma skin cancer development: Research

New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease.

30 Nov 2010

Celulas Genetica licenses new organ regeneration treatment from Chinese BBFITCL

Emerging Healthcare Solutions, Inc. announced today that its affiliate, Celulas Genetica, purchased a license to develop and market a revolutionary new medical treatment known as the Rutherford Procedure.

30 Nov 2010

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 2b clinical trial of its Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004.

30 Nov 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

Evidence of evolutionary protection against inbreeding in women?

Through an innovative use of cell phone records, researchers at UCLA, the University of Miami and Cal State, Fullerton, have found that women appear to avoid contact with their fathers during ovulation.

30 Nov 2010

Intellikine and MMRC commence INK128 Phase I trial in multiple myeloma

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.

30 Nov 2010

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

University Hospitals receives $42 million for cancer care

Jane and Lee Seidman have donated $42 million to University Hospitals (UH) the largest gift in the Cleveland-based health system's history. In recognition of this unprecedented generosity, UH is naming the "Jane and Lee Seidman Cancer Center" in their honor.

30 Nov 2010

miRagen and t2cure enter licensing agreement for microRNA 92 technology

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced today that they have entered into a licensing agreement

30 Nov 2010